Browsing Tag
Biocon Biologics Limited
4 posts
Biocon Biologics (NSE: BIOCON) clears global aflibercept deal with Regeneron, Bayer for Yesafili rollout
Biocon Biologics secures global aflibercept launch rights for Yesafili after Regeneron–Bayer settlement. Find out what this means for biosimilar strategy.
Biocon goes all-in on biosimilars with $5.5bn Biocon Biologics merger and Viatris exit
Biocon to merge Biocon Biologics in $5.5B deal with full ownership via share swap and cash. Find out what it means for investors and global biosimilar strategy.
Can Biocon’s Kirsty become the Semglee of rapid-acting insulin in the US market?
Can Biocon Biologics repeat Semglee’s U.S. success with Kirsty? Find out if PBM coverage and pricing will fuel rapid adoption in the $1.9B insulin market.
Biocon secures FDA nod for Kirsty: Can the first interchangeable rapid-acting insulin aspart disrupt the US diabetes market?
Biocon Biologics wins FDA nod for Kirsty insulin, boosting Biocon shares. Can this $1.9B U.S. biosimilar opportunity reshape diabetes care?